These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 1705062)
41. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma]. Stamey TA Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883 [TBL] [Abstract][Full Text] [Related]
42. Sentinel lymph node dissection in more than 1200 prostate cancer cases: rate and prediction of lymph node involvement depending on preoperative tumor characteristics. Winter A; Kneib T; Henke RP; Wawroschek F Int J Urol; 2014 Jan; 21(1):58-63. PubMed ID: 23659488 [TBL] [Abstract][Full Text] [Related]
44. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT. Borley N; Fabrin K; Sriprasad S; Mondaini N; Thompson P; Muir G; Poulsen J Scand J Urol Nephrol; 2003; 37(5):382-6. PubMed ID: 14594685 [TBL] [Abstract][Full Text] [Related]
45. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698 [TBL] [Abstract][Full Text] [Related]
46. Fluorescence Guided Targeted Pelvic Lymph Node Dissection for Intermediate and High Risk Prostate Cancer. Hruby S; Englberger C; Lusuardi L; Schätz T; Kunit T; Abdel-Aal AM; Hager M; Janetschek G J Urol; 2015 Aug; 194(2):357-63. PubMed ID: 25896557 [TBL] [Abstract][Full Text] [Related]
47. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Briganti A; Abdollah F; Nini A; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni NM; Salonia A; Colombo R; Freschi M; Rigatti P; Montorsi F Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610 [TBL] [Abstract][Full Text] [Related]
48. [Preoperative assessment of tumor aggressiveness in localized prostatic carcinoma]. Hammerer P; Henke RP; Hübner D; Huland H Urologe A; 1995 Sep; 34(5):413-8. PubMed ID: 7483160 [TBL] [Abstract][Full Text] [Related]
49. Value of prostate-specific antigen in the staging of Taiwanese patients with newly diagnosed prostate cancer. Meng E; Sun GH; Wu ST; Chuang FP; Lee SS; Yu DS; Yen CY; Chen HI; Chang SY Arch Androl; 2003; 49(6):471-4. PubMed ID: 14555332 [TBL] [Abstract][Full Text] [Related]
51. The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy? Gingrich JR; Paulson DF Surg Oncol Clin N Am; 1995 Apr; 4(2):335-44. PubMed ID: 7540939 [TBL] [Abstract][Full Text] [Related]
52. [Reliability of CT for determining lymphatic involvement in patients with prostate cancer]. Amo FH; Verdú Tartajo F; Díez Cordero JM; Lledó García E; Bueno Chomón G; Leal Hernández F Arch Esp Urol; 1997 Jun; 50(5):464-8. PubMed ID: 9382588 [TBL] [Abstract][Full Text] [Related]
53. Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool. Kluth LA; Abdollah F; Xylinas E; Rieken M; Fajkovic H; Sun M; Karakiewicz PI; Seitz C; Schramek P; Herman MP; Becker A; Loidl W; Pummer K; Nonis A; Lee RK; Lotan Y; Scherr DS; Seiler D; Chun FK; Graefen M; Tewari A; Gönen M; Montorsi F; Shariat SF; Briganti A Eur Urol; 2014 Sep; 66(3):439-46. PubMed ID: 23850255 [TBL] [Abstract][Full Text] [Related]
56. Staging lymphadenectomy should be an antecedent to treatment in localized prostatic carcinoma. Olsson CA Urology; 1985 Feb; 25(2 Suppl):4-6. PubMed ID: 3969765 [TBL] [Abstract][Full Text] [Related]
57. Overtreatment of prostate cancer may be prevented by extended pelvic lymphadenectomy. Azawi NH; Stenfeldt K; Christensen T Dan Med J; 2013 Sep; 60(9):A4709. PubMed ID: 24001469 [TBL] [Abstract][Full Text] [Related]
58. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854 [TBL] [Abstract][Full Text] [Related]
59. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer. Stone NN; Stock RG Mt Sinai J Med; 1999 Jan; 66(1):26-30. PubMed ID: 9989102 [TBL] [Abstract][Full Text] [Related]